


## Verseau Therapeutics

Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. With a proprietary all-human translational system Verseau identifies novel targets and develops therapies that shift macrophages between immune activators and silencers in disease. Verseau's data suggest that the patient population benefitting from immunotherapy can be at least doubled. The company's initial focus is building a pipeline of first-in-class therapies that modulate macrophages to trigger a coordinated immune attack on cancer.

## Macrophage Checkpoint Modulators

Verseau is broadening the therapeutic potential of immunotherapy by developing macrophage checkpoint modulators (MCMs) that regulate the functional shift to make macrophages more inflammatory or more tolerogenic depending on the disease context. While PD-1 inhibitors have provided great clinical successes, they are only effective in 10-15% of cancer patients. Macrophages demonstrate one of the highest infiltration rates in human tumors (~75%<sup>\*</sup>). MCMs cause tumors to turn highly inflammatory and stimulate multiple immune cell types, including T cells. Verseau's therapies have the potential to significantly expand the number of patients benefitting from immunotherapy, including those unresponsive to PD-1 inhibitor therapies.



Founded  
in 2017

Multiple validated  
novel targets

Validated targets amenable to  
monoclonal antibodies, small  
molecules and nucleic acid

Applicability in  
cancer, immune and  
inflammatory diseases

## The Verseau Platform

Verseau is developing a pipeline of potential first-in-class antibody therapies with an initial focus in cancer and follow-on programs in conditions with excessive inflammation. The Company utilizes its deep myeloid cell knowledge and advanced computational biology capabilities to identify novel macrophage checkpoints and employ its proprietary siRNA reagents and delivery technology to validate targets in primary human cells. Through its proprietary all-human translational system Verseau has validated more than two dozen targets amenable to different therapeutic modalities, including monoclonal antibodies (mAbs).

## Macrophage Targeting Immunotherapies

In patient derived primary tumors, several of Verseau's macrophage checkpoint modulators (MCMs) are shown to induce tumor microenvironment activation, T cell activation and naïve immune cell recruitment amounting to a coordinated immune attack. This activity is seen when Verseau's MCMs are engaged as a monotherapy in both PD-1 responders and non-responders. The MCMs also demonstrate additivity to PD-1 inhibition. Verseau has several ongoing mAb programs and anticipates advancing into IND-enabling studies in the near term. Verseau is diligently working to bring these potential therapies to patients who are not currently seeing enough or any benefit from immunotherapy.

\*Proprietary Genomic Analysis by Verseau: 10,000 cancer patients across 33 tumor types

## Investors

20/20 HealthCare Partners  
Alexandria Venture Investments  
InHarv Partners

Highlight Capital  
The Mark Foundation  
Yonghua Capital

## Team

### Executive Team

---

**Christine Bunt, Ph.D.**

Chief Executive Officer and  
Chairman of the Board

**Robert Crane, MBA**

Chief Financial Officer

**Igor Feldman, Ph.D.**

Co-Founder and Head of  
Computational Biology

**Tatiana Novobrantseva, Ph.D.**

Co-Founder and Head of  
Research and Development

### Board of Directors

---

**Christine Bunt, Ph.D.**

Chief Executive Officer and  
Chairman, Verseau

**Dan Anderson, Ph.D.**

Co-Founder, Verseau  
Professor, Applied Biology, Koch  
Institute, MIT

**Jong Chang, MBA**

Founder & Chairman, InHarv  
Partners

**Wen Chen, MBA**

Senior Vice President, Tigermed  
Co. Ltd.

**Bob Langer, Ph.D.**

Co-Founder, Verseau  
David H. Koch Professor, Koch  
Institute, MIT

### Advisors

---

**Antoine Awad**

Senior Advisor, Verseau  
Head of Technical Operations,  
Synlogic Therapeutics

**George Columbeski, Ph.D.**

Senior Advisor, Verseau  
President, Head of Corporate  
Development and Strategy, Grail